First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor

• Main Authors: Vidya Perera (Author), Zhaoqing Wang (Author), Joseph Luettgen (Author), Danshi Li (Author), Mary DeSouza (Author), Michael Cerra (Author), Dietmar Seiffert (Author)
• Format: Book
• Published: Wiley, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Milvexian (BMS‐986177/JNJ‐70033093) is a small molecule, active‐site inhibitor of factor XIa (FXIa) being developed to prevent and treat thrombotic events. The safety, tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of milvexian were assessed in a two‐part, double‐blind, pl...